David Cuellar, MD
Urology · Round Rock, TXNPI 1376519330
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $269,927 of the $342,636 with a category attached, or 78.8%. Procept Biorobotics Corporation accounts for 83.7% of it on its own, with 38 other manufacturers making up the rest. 2025 is the largest year on record at $129,382, more than ten times the $4,810 reported in 2019. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 385 payments — averaging $889.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$287K
- Intuitive Surgical$34K
- Strauss Surgical USA LLC$17K
- Johnson & Johnson$694
- Teleflex LLC$513
- AbbVie$342
- plus $3K from 33 others
Across 4 payments — averaging $12,076 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Calyxo, Inc.$48K
What the payments were for
- Consulting fees$269,92779%
- Speaking & faculty fees$17,6005%
- Travel & lodging$9,8303%
- Food & beverage$14,2654%
- Education$31,0159%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 187 | $286,691 |
| Intuitive Surgical | 29 | $34,409 |
| Strauss Surgical USA LLC | 1 | $17,100 |
| Johnson & Johnson(2 entities) | 22 | $694 |
| Teleflex LLC | 8 | $513 |
| AbbVie(2 entities) | 18 | $342 |
| Pfizer | 16 | $267 |
| Astellas Pharma US Inc | 13 | $243 |
| Calyxo, Inc. | 3 | $238 |
| Dendreon Pharmaceuticals LLC | 8 | $226 |
| Ferring Pharmaceuticals Inc. | 7 | $225 |
| Smith+Nephew | 2 | $149 |
| AstraZeneca | 5 | $147 |
| Bayer | 6 | $114 |
| Myovant Sciences Inc. | 5 | $109 |
| Sumitomo Pharma America, Inc. | 5 | $106 |
| Travere Therapeutics, Inc. | 5 | $85 |
| Olympus America Inc. | 2 | $83 |
| Endo Pharmaceuticals Inc. | 6 | $82 |
| BD | 1 | $80 |
| Myriad Genetic Laboratories, Inc. | 3 | $66 |
| Progenics Pharmaceuticals, Inc. | 1 | $65 |
| Merck | 3 | $62 |
| Antares Pharma, Inc. | 3 | $59 |
| Immunitybio, Inc. | 2 | $58 |
| Boston Scientific | 3 | $55 |
| Halozyme Inc | 3 | $53 |
| Urogen Pharma, Inc. | 3 | $52 |
| Sun Pharmaceutical Industries Inc. | 2 | $49 |
| Clarus Therapeutics Inc. | 2 | $42 |
| Blue Earth Diagnostics | 2 | $34 |
| Tolmar Pharmaceuticals, Inc. | 2 | $30 |
| Accord Healthcare, Inc. | 1 | $19 |
| Endo USA, Inc. | 1 | $18 |
| Stryker | 1 | $17 |
| Verity Pharmaceuticals Inc. | 1 | $17 |
| Neotract Inc. | 1 | $16 |
| Covidien LP | 1 | $13 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$170,314
- AQUABEAM SYSTEM$112,499
- Da Vinci Surgical System$33,745
- MCB Bipolar Resection Generator and electrode$17,100
- DA VINCI SP$500
- Erleada$277
- UroLift System$251
- Stravix$131
- CVAC$107
How this compares
$342,636 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 64 | $168,795 |
| MyrbetriqMirabegron | 79 | $68,605 |
| Mirabegron ErMirabegron | 17 | $11,003 |
| Tamsulosin Hcl | 568 | $7,159 |
| Finasteride | 432 | $5,268 |
| Solifenacin Succinate | 81 | $3,067 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 89 | $2,398 |
| Potassium Citrate ErPotassium Citrate | 12 | $1,453 |
| Testosterone Cypionate | 28 | $1,300 |
| Estradiol | 17 | $1,182 |
| Oxybutynin Chloride ErOxybutynin Chloride | 34 | $1,138 |
| Dutasteride | 23 | $511 |
| Allopurinol | 15 | $149 |
| Hydrochlorothiazide | 20 | $149 |
| Ciprofloxacin Hcl | 37 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx | $106 | $168,79564 claims |
| Astellas Pharma US IncMyrbetriq | $243 | $68,60579 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 urology providers in Texas.
Other urology in Round Rock
- Sandeep MistryRound Rock$82K
- Carl BischoffRound Rock$53K
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
- Arun RaiHouston$920K
- Allen MoreyDallas$914K
- Donald GriffithHouston$732K
- Michael TrotterAustin$590K
- Vitaly MargulisDallas$555K
- Daniel SaltzsteinSan Antonio$547K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.